Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 03, 2020 00:00 ET | Source: RadioMedix Inc.

RadioMedix selected for 2019-2020 NIH SBIR/STTR Commercialization Accelerator Program (CAP)

Houston, Jan. 03, 2020 (GLOBE NEWSWIRE) -- RadioMedix Inc. is pleased to announce that the company has been selected for the 2019-2020 Commercialization Accelerator Program (CAP) by the National...
January 22, 2019 10:00 ET | Source: RadioMedix Inc.

RadioMedix received $2.0 M SBIR Phase II Contract award from NCI NIH for the targeted alpha-emitter therapy of neuroendocrine cancers.

Houston (TX), Jan. 22, 2019 (GLOBE NEWSWIRE) -- RadioMedix Inc. is pleased to announce that the company has been awarded a two-years, $2.0 M Phase II SBIR contract award by the NIH NCI...
January 09, 2019 01:00 ET | Source: RadioMedix Inc.

RadioMedix and Curium Announce FDA Fast Track Designation For 64Cu-Dotatate.

Houston, TX and St. Louis, MO, Jan. 09, 2019 (GLOBE NEWSWIRE) -- RadioMedix Inc. and its commercial partner Curium announced today that their investigational diagnostic radiopharmaceutical,...
November 13, 2018 10:00 ET | Source: RadioMedix Inc.

RadioMedix and Orano Med receive FDA Orphan Drug Designation for AlphaMedix (TM) for the treatment of neuroendocrine tumors

Houston (TX U.S.), Courbevoie (France), Nov. 13, 2018 (GLOBE NEWSWIRE) -- RadioMedix Inc. (a Texas-based clinical stage biotechnology company) and Orano Med (a nuclear biotechnology company)...
July 26, 2018 05:00 ET | Source: RadioMedix Inc.

RadioMedix and ITM announce agreement for manufacturing of Ge-68/Ga-68 generators in U.S.

Houston (TX, USA) and Garching (Germany), July 26, 2018 (GLOBE NEWSWIRE) -- RadioMedix Inc. and ITM Isotopen Technologien München (ITM), a specialized radiopharmaceutical group of companies...
January 10, 2018 05:00 ET | Source: RadioMedix Inc.

RadioMedix and AREVA Med announce initiation of Phase 1 clinical trial of AlphaMedix(TM), a Targeted Alpha Therapy for patients with neuroendocrine tumors

Houston, TX (USA) and Courbevoie (France), Jan. 10, 2018 (GLOBE NEWSWIRE) -- RadioMedix Inc. and AREVA Med today announced the initiation in the United States of Phase 1 trial for AlphaMedixTM in...
October 17, 2017 08:08 ET | Source: RadioMedix Inc.

RadioMedix Selected for National Cancer Institute’s Investor Initiatives and Presentation at BIO Investor Forum

Houston TX, Oct. 17, 2017 (GLOBE NEWSWIRE) -- Houston, TX--RadioMedix Inc. a clinical-stage company, announced that it has been selected to present at the prestigious Biotechnology...
October 11, 2017 06:00 ET | Source: RadioMedix Inc.

Extended partnership between Radiomedix INC and ITM´s subsidiary ITG for exclusive distribution of n.c.a Lutetium-177 in North America

Houston, TX, Oct. 11, 2017 (GLOBE NEWSWIRE) -- RadioMedix Inc, a biotechnological company, focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring and therapy of cancer, and...
June 22, 2017 16:00 ET | Source: RadioMedix Inc.

RadioMedix Inc. and AREVA Med Announce Completion of the Exploratory Clinical Trial of 203Pb-AR-RMX in patients expressing somatostatin receptor positive neuroendocrine tumors

Houston, TX; Plano, TX, June 22, 2017 (GLOBE NEWSWIRE) -- RadioMedix Inc and AREVA Med announced today the completion of the exploratory clinical trial evaluating the biodistribution...
February 06, 2017 06:00 ET | Source: RadioMedix Inc.

First U.S. Multi-center Investigational Clinical Trial of 177 Lu PSMA-617 Targeted Radioligand Therapy in Metastatic Castration Resistant Prostate Cancer Receives FDA Clearance

Houston, TX; Los Angeles, CA, Feb. 06, 2017 (GLOBE NEWSWIRE) -- RadioMedix, Excel Diagnostics and Nuclear Oncology Center (EDNOC), and the Ahmanson Translational Imaging...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right